Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL682830 | 0.90 | ADORA2B (0.50) | HTR2AHTR7HTR6ADORA2BGLA | |
| SCHEMBL684026 | 0.88 | MAPK1 (0.49) | HTR2AHTR7HTR6ADORA2BGLA | |
| SCHEMBL683652 | 0.88 | MAPK1 (0.55) | HTR2AGLAMAPK1TSHRALDH1A1 | |
| SCHEMBL684375 | 0.87 | ADORA2B (0.53) | HTR2AADORA2BKMT2AMAPK1TSHR | |
| SCHEMBL684068 | 0.87 | ADORA2B (0.50) | HTR2AHTR7ADORA2BMAPK1 | |
| SCHEMBL683668 | 0.86 | ADORA2B (0.49) | HTR2AADORA2BGLABLM | |
| SCHEMBL684062 | 0.86 | HTR2A (0.52) | HTR2AADORA2BGLABLMKMT2A | |
| SCHEMBL684065 | 0.86 | HTR2A (0.52) | HTR2AHTR7ADORA2BGLABLM | |
| SCHEMBL683646 | 0.86 | HTR2A (0.52) | HTR2AADORA2BGLABLMKMT2A | |
| SCHEMBL684377 | 0.86 | MAPK1 (0.47) | HTR2AHTR7HTR6ADORA2BGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | HTR2A 1201/4885HTR7 1398/4885HTR6 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.